About Event
The 3rd Kinase Targeted Drug Discovery Summit returned in 2025:
Experiencing Kinase Transformation - Where Innovation Met Collaboration
Your colleagues joined this free-to-attend forum dedicated to drug developers and researchers in the kinase community! This was your chance to connect with 80+ leading experts in biology, chemistry, drug discovery, proteomics, and structural biology – all focused on advancing kinase therapeutics!
Building on the previous year’s success, our attendees learned about cutting-edge advancements within kinase biology. Whether through maximizing mutant-selective inhibition or optimizing PK/PD safety profiles, they met at the future of kinase drug discovery.
Despite the industry’s continued exploration of small molecule inhibitors against kinases, there are still challenges of selectivity and resistance that pose to be a limitation in their therapeutic applications. This has spurned the growth of new and exciting approaches to targeting kinases that aim to overcome the limitations that first-generation kinase inhibitors have faced, spearheaded by recent developments from the likes of Biogen, A-Alpha Bio, and Proxygen within the targeted protein degradation space.
What did you miss in February?
Complimentary Access for Drug Developers & Academics
Discovering Cutting-Edge Research
Expanding Your Network & Collaborate
Our delegates from Biopharma took advantage of free attendance to gain unrivalled insights to create the best and first-in-class kinase targeted drugs. Through innovations in small molecule therapeutics and novel approaches using PROTACs, molecular glues, and allosteric inhibitors – this in-depth meeting helped them connect with the most suitable high-in-demand technologies to aid their work.
Stay ahead in your field by exploring the latest advancements in kinase drug development. Your colleagues gained insights from case studies on a wide range of presentations from experts in kinase biology, enabling them to develop drugs with enhanced selectivity, tackle resistance, and identify the perfect combination partners.
With numerous networking opportunities, including a dedicated speed networking session, this summit was an essential platform to exchange challenges, share insights, and inspire solutions to leave your mark across the entire kinase community.
Unmissable Key Sessions in 2025
Reimagining the industry’s approach to structure-guided design by harnessing AI and machine learning to detect conformational changes and improve compound-kinase bioactivity prediction with Harmonic Discovery
Dissecting the mode of action for non-ATP competitive, isoform-specific inhibition of PI3Kd by monitoring its pharmacological activity to achieve a selectivity-matched PK profile and optimize its therapeutic potential with iOnctura
Identifying signs of clinical resistance by extrapolating free energy calculations of protein-residue-mutation from physics-based modeling to unlock kinome-wide selectivity of WEE1 as well as DLK inhibitors with Schrodinger
Implementing ground-breaking solutions to mutant-selective TYK inhibition by targeting ERBB2 through the discovery of Bayer’s new small molecule inhibitor to combat non-small cell lung cancer (NSCLC) with Dana-Farber Cancer Institute
Who You Could Have Met
This unique forum was your golden ticket to join and network with 80+ kinase drug developers, researchers, and solution providers – all under one roof – with the shared interest of improving previous generations of kinase therapeutics, and hear from leading service providers showcasing game-changing technologies in kinase assays, phospho-proteomic profiling, AI drug design, and cryo-EM!
What Past Attendees Have Said
"Focused meeting with some really high-quality science shared and discussed"
Senior Vice President, Black Diamond Therapeutics
"A valuable event because of the quality of the talks and the dialogue following the talks. Very unique opportunity"
President & Chief Executive Officer, Onconova Therapeutics
"This meeting was a time well spent, between various great and diverse presentations and networking with colleagues and CROs"
Vice President, TG Therapeutics